Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;96(7):1136-1149.
doi: 10.1002/jnr.24220. Epub 2018 Mar 1.

The neuroprotective role of melatonin in neurological disorders

B S Alghamdi  1   2
Affiliations
Review

The neuroprotective role of melatonin in neurological disorders

B S Alghamdi. J Neurosci Res. 2018 Jul.

Abstract

Melatonin is a neurohormone secreted from the pineal gland and has a wide-ranging regulatory and neuroprotective role. It has been reported that melatonin level is disturbed in some neurological conditions such as stroke, Alzheimer's disease, and Parkinson's disease, which indicates its involvement in the pathophysiology of these diseases. Its properties qualify it to be a promising potential therapeutic neuroprotective agent, with no side effects, for some neurological disorders. This review discusses and localizes the effect of melatonin in the pathophysiology of some diseases.

Keywords: alzheimer; ischemia; melatonin; parkinson.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ischaemia pathophysiology at four stages: energy failure, excitotoxicity, oxidative stress and inflammation. (formula image) Represents the site of melatonin action
Figure 2
Figure 2
Alzheimer's pathophysiology with melatonin site of action (formula image)
Figure 3
Figure 3
Parkinson's disease pathophysiology with melatonin site of action (formula image)
See this image and copyright information in PMC

References

    1. Acuna‐Castroviejo, D. , Coto‐Montes, A. , Gaia Monti, M. , Ortiz, G. G. , & Reiter, R. J. (1997). Melatonin is protective against MPTP‐induced striatal and hippocampal lesions. Life Sciences, 60(2),Pl23–29. - PubMed
    1. Adi, N. , Mash, D. C. , Ali, Y. , Singer, C. , Shehadeh, L. , & Papapetropoulos, S. (2010). Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Medical Science Monitor, 16(2), Br61–67. - PubMed
    1. Ali, T. , & Kim, M. O. (2015). Melatonin ameliorates amyloid beta‐induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3beta pathway in the mouse hippocampus. Journal of Pineal Research, 59(1), 47–59. https://doi.org/10.1111/jpi.12238 - DOI - PubMed
    1. Alluri, H. , Wilson, R. L. , Anasooya Shaji, C. , Wiggins‐Dohlvik, K. , Patel, S. , Liu, Y. , … Tharakan, B. (2016). Melatonin Preserves Blood‐Brain Barrier Integrity and Permeability via Matrix Metalloproteinase‐9 Inhibition. PLoS One, 11(5), e0154427 https://doi.org/10.1371/journal.pone.0154427 - DOI - PMC - PubMed
    1. Alvarez, A. , Alarcon, R. , Opazo, C. , Campos, E. O. , Munoz, F. J. , Calderon, F. H. , … Inestrosa, N. C. (1998). Stable complexes involving acetylcholinesterase and amyloid‐beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. Journal of Neuroscience, 18(9), 3213–3223. - PMC - PubMed